In recent years, China’s medical aesthetics industry is undergoing a transformative leap from the “filling era” to the “regeneration era.” Against the backdrop of the country’s strategic focus on regenerative medicine, breakthroughs in new biomaterials and synthetic biology technologies have become the core driving forces of the industry. Currently, the regenerative materials market is leading the medical aesthetics sector with an annual growth rate exceeding 30%, and it is expected that the active materials market size will surpass 100 billion yuan by 2030. Meanwhile, synthetic biology is promoting large-scale production of raw materials such as recombinant collagen and PHA microspheres through gene editing and cell factory technologies, providing new paths for innovation in medical aesthetics materials.

However, the industry still faces challenges in technology transfer, clinical validation, and compliance. This forum aims to explore synergistic innovations in new material development and clinical applications, fostering high-quality industry growth.

• Medical device manufacturers: heads of the departments of R&D, design, and technology, as well as project/company leaders
• Medical beauty materials and equipment suppliers and service providers
• Doctors, and research institutes, etc.